DNA sequence encoding a novel glucuronyl C5-epimerase

Details DNA sequence encoding a novel glucuronyl C5-epimerase DNA sequence encoding a novel glucuronyl C5-epimerase

1999-10-18

2004-07-20

Puty, Rebecca (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Isomerase

C435S320100, C435S348000, C435S252330, C435S358000, C435S365000, C435S369000, C435S252300, C435S325000, C435S233000, C536S023200, C536S023500, C536S023400

Reexamination Certificate

active

06764844

ABSTRACT:

The present invention relates to an isolated or recombinant DNA sequence coding for a glucuronyl C5-epimerase capable of converting D-glucuronic acid to L-iduronic acid. The invention also relates to a process for the manufacture of such epimerase.
BACKGROUND OF THE INVENTION
Heparin and heparan sulfate are complex, sulfated glycosaminoglycans composed of alternating glucosamine and hexuronic acid residues. The two polysaccharides are structurally related but differ in composition, such that heparin is more heavily sulfated and shows a higher ratio of L-iduronic acid (IdoA)/D-glucuronic acid (GlcA) units (Kjellén, Land Lindahl, U. (1991)
Annual Review of Bio-chemistry
60, 443-475; Salmivirta, M., Lidholt, K. and Lindahl, U. (1996)
The FASEB Journal
10, 1270-1279). Heparin is mainly produced by connective tissue-type mast cells, whereas heparan sulfate has a ubiquitous distribution and appears to be expressed by most cell types. The biological roles of heparin and heparan sulfate are presumably largely due to interactions of the polysaccharides with proteins, such as enzymes, enzyme inhibitors, extracellular-matrix proteins, growth factors/cytokines and others (Salmivirta, M., Lidholt, K. and Lindahl, U. (1990)
The FASEB Journal
10, 1270-1279). The ineractions tend to be more or less selective/specific with regard to carbohydrate structure, and thus depend on the amounts and distribution of the various sulfate groups and hexuronic acid units. Notably, IdoA units are believed to generally promote binding of heparin and heparan sulfate chains to proteins, due to the marked conformational flexibility of these residues (Casu, E., Petitou, M., Provasoli, M. and Sinay, P. (1988)
Trends in Biochemical Sciences
13, 221-225).
Heparin and heparan sulfate are synthesized as pro-teoglycans. The process is initiated by glycosylation reactions that generate saccharide sequences composed of alternating GlcA and N-acetylglucosamine (GlcNAc) units covalently bound to peptide core structures. The resulting (GlcA&bgr;1,4-GlcNAcal,4-)
n
disaccharide repeats are modified, probably along with chain elongation, by a series of enzymatic reactions that is initiated by N-deacetylation and N-sulfation of GlcNAc units, continues through C-5 epimerization of GlcA to IdoA residues, and is concluded by the incorporation of O-sulfate groups at various positions. The N-deacetylation/N-sulfation step has a key role in determining the overall extent of modification of the polymer chain, since the GlcA C-5 epimerase as well as the various O-sulfotransferases all depend on the presence of N-sulfate groups for substrate recognition. While the GlcNAc N-deacetylation and N-sulfation reactions are both catalyzed by the same protein, isolation and molecular cloning of N-deacetylase/N-sulfotransferase from different tissue sources implicated two distinct forms of the enzyme. The two enzyme types differ with regard to kinetic properties, and it has been suggested that they may be differentially involved in the biosynthesis of heparin and heparan sulfate.
SUMMARY OF THE INVENTION
The present invention provides for an isolated or recombinant DNA-sequence coding for a mammalian, including human, glucuronyl C-5 epimerase or a functional derivative thereof capable of converting D-glucuronic acid (GlcA) to L-iduronic acid (IdoA).
The invention also provides for a recombinant expression vector containing a transcription unit comprising a DNA sequence as described above, a transcriptional promoter, and a polyadenylation sequence.
The invention also provides for a process for the manufacture of a glucuronyl C-5 epimerase or a functional derivative thereof capable of converting D-glucuronic acid (GlcA) to L-iduronic acid (IdoA), comprising cultivation of a cell line transformed with the above recombinant expression vector in a nutrient medium allowing expression and secretion of said epimerase or functional derivative thereof.
Specific DNA sequences according to the invention are defined in the Sequence Listing.
Furthermore, the invention provides for a host cell transformed with such recombinant expression vector.
Finally, the invention covers a glucuronyl C-5 epimerase or a functional derivative thereof whenever prepared by the process outlined above.


REFERENCES:
patent: 5939289 (1999-08-01), Ertesvåg et al.
patent: 6372477 (2002-04-01), Jøosboe et al.
patent: WO 01/38507 (2001-05-01), None
patent: WO96/14425 (1996-05-01), None
patent: WO 98/48006 (1998-10-01), None
Voet et al. “Biochemistry”, 2nd Ed., John Wiley and Sons, Inc., 1995.*
Xue et al. Cell 72(5):681-693 (1993).*
Wilson et al. Nature 368(6466):32-38 (1994).*
NCBI Entrez, GenBank Report, Accession No. AAF57373, from Adams, M.D. et al. (Mar. 2000).
Crawford, B.E. et al., “Cloning, Golgi Localization, and Enzyme Activity of the Full-length Heparin/Heparan Sulfate-Glucuronic Acid C5-epimerase”,J. Biol. Chem. 276:21538-21543, The American Society for Biochemistry and Molecular Biology, Inc. (Jun. 2001).
Féthière, J. et al., “Crystal Structure of Chondroitin AC Lyase, a Representative of a family of Glycosaminoglycan Degrading Enzymes,”J. Mol. Biol. 288:635-647, Academic Press (May 1999).
Dialog File 351, Accession No. 2001-381292/200140, Derwent WPI English language abstract for WO 01/38507 (May 31, 2001).
NCBI Entrez, GenBank Report, Accession No. P46555, from Sulston, J. (1994).
NCBI Entrez, GenBank Report, Accession No. AF043700, from Wilson, R. et al. (1998).
NCBI Entrez, GenBank Report, Accession No. AAF36018, from The C. elegans Sequencing Consortium et al. (1998).
Ron, D. et al., “Expression of Biologically Active Recombinant Keratinocyte Growth Factor. Structure/Function Analysis of Amino-Terminal Truncation Mutants,”J. Biol. Chem. 268:2984-2988, American Society of Biochemistry Molecular Biology Inc. (1993).
NCBI Entrez, GenBank Report, Accession No. LO8483, from Xue, F. et al. (1993).
Database Biosis Biosciences Information Service, Database accession No. PREV200000122890, abstract for Hagner-McWhirter, A. et al., “Biosynthesis of herparin/heparan sulphate: Kinetic studies of the glucuronyl C5-epimerase with N-sulfated derivatives of theEscherichia coliK5 capsular polysaccharide as substrates,” (Feb. 2000).
D-glucuronyl C5-epimerase amino acid sequence (EC 5.1.3.-), Accession No. 094923, Database EBI [Online] (May 1999).
Nagase, T. et al., “Prediction of the Coding Sequence of Unidentified Human Genes. XII. The Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteins in vitro,”DNA Res. 5:355-364, Tokyo Kazusa DNA Research Institute and Universal Academy Press (1998).
D-glucuronyl C5-epimerase (EC 5.1.3.-) amino acid sequence (mouse), Accession No. Q9EPS3, Database EBI [Online] (Mar. 2001).
D-glucuronyl C5-epimerase (EC 5.1.3.-) amino acid sequence (bovine), Accession No. 018756, Database EBI [Online] (Jan. 1998).
Kelley, L.A. et al., “Enhanced Genome Annotation Using Structural Profiles in the Program 3D-PSSM,”J. Mol. Biol. 299:499-520, Academic Press (Jun. 2000).
Li, J.-p. et al., “Biosynthesis of Heparin/Heparan Sulfate. cDNA Cloning and Expression of D-Glucuronyl C5-Epimerase from Bovine Lung.,”J. Biol. Chem. 272:28158-28163, The American Society for Biochemistry and Molecular Biology, Inc. (1997).
Malmström, A. et al., “Biosynthesis of Heparin. Partial Purification of the Uronosyl C-5 Epimerase,”J. Biol. Chem. 255:3878-3883, American Society of Biochemistry and Molecular Biology Inc. (1980).
Hagner-McWhirter, ↑. et al., “Biosynthesis of heparin/heparin sulfate: kinetic studies of the glucuronyl C5-epimerase with N-sulfated derivatives of theEsherichia coliK5 capsular polysaccharide as substrates,” Glycobiology 10:159-171, Oxford University Press (Feb. 2000).
Hagner-McWhirter, Å. et al., “Biosynthesis of heparin/heparan sulphate: mechanism of epimerization of glucuronyl C-5,”Biochem J. 347:69-75, London Portland Press On Behalf Of The Biochemical Society (Apr. 2000).
“Conformational flexibility: a new concept for explaining binding and biological properties of iduronic

Affiliated with

Also associated with

Rating

DNA sequence encoding a novel glucuronyl C5-epimerase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DNA sequence encoding a novel glucuronyl C5-epimerase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA sequence encoding a novel glucuronyl C5-epimerase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3202211